A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Study Summary

This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.

Conditions

SST2-positive Neuroendocrine Neoplasms Neuroendocrine Tumors Neuroendocrine Neoplasm

Interventions / Drugs

CRN09682

View on ClinicalTrials.gov ↗

Sponsor

CRNX

Crinetics Pharmaceuticals

Endocrinology

D39/100

Study Details

Enrollment150 participants

Primary Completion—

Lead SponsorCrinetics Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:10:51.260357+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.